Hims & Hers Health has launched a partnership with Novo Nordisk to distribute a broad portfolio of FDA-approved GLP-1 therapies, including the Wegovy weight loss pill. Eligible customers can subscribe to treatments starting at $149 per month, encompassing both injection and oral dosing formats.

The deal positions Hims & Hers as the largest direct-to-consumer platform for affordable metabolic medications, enhancing its competitive stance in the rapidly expanding obesity treatment market. By leveraging Novo Nordisk's pipeline and Hims & Hers digital infrastructure, the companies aim to accelerate patient access and scale subscription revenues.